Overview:
The American College of Obstetricians and Gynecologists states that around 5%-25% pregnant women experience postpartum depression in America. This growing prevalence primarily contribute to the lucrativeness of this market. Rising awareness among women with respect to postpartum depression has further catalysed the market growth. Growing research activities among leading industries in developing suitable pharmacological treatment option increases the market attractiveness and inclination of women towards timely treatment.
Antidepressants are prescribed for this condition at controlled dosages. No targeted therapy for postpartum depression has yet been approved owing to its complexity associated with lactating mothers. SAGE-547 (brexanolone) a phase 3 molecule and SAGE-217 a phase 2 molecule of SAGE Therapeutics, Inc. (Hummingbird Program) is being developed for the treatment of postpartum depression. SAGE-547 (brexanolone) achieved positive primary results of reduction in HAM-D (Hamilton Depression Rating Scale) score compared to placebo in its phase 3 trials. A reduction in depressive symptoms within 30 days was observed during this trial. Approval of brexanolone would catalyse the overall postpartum depression treatment market in the forecast period from 2018 to 2026, as it would be the first approved targeted drug therapy for postpartum depression.
North America accounted for largest market share in 2017 and continues its dominancy through 2026 as well. North America witnessed high number of teenage pregnancy cases, which is one of the primary reasons causing postpartum depression. As per the Centers for Disease Control and Prevention, a birth rate of 22.3 per 1000 women aged 15-19 years was reported. This growing incidence facilitates the overall market growth in North America. Asia Pacific projects sluggish growth in postpartum depression treatment market during the forecast period due to lack of awareness on the condition and lower patient acceptance on psychiatric conditions.
Suitable diagnosis for postpartum depression is one of the major unmet need, which could restraint the overall market growth. Additionally, the unacceptance and negligence of postpartum depression among patients could also have a negative impact on the market growth.
The Global Postpartum Depression Treatment Market is segmented as follows:
- By Drug Class
- Selective Serotonin Reuptake Inhibitors
- Citalopram
- Escitalopram
- Fluoxetine
- Fluvoxamine
- Paroxetine
- Sertaline
- Serotonin Norepinephrine Reuptake Inhibitors
- Desvenlafaxine
- Duloxetine
- Venlaflaxine
- Other Antidepressants
- Bupropion
- Nefazodone
- Trazodone
- Mirtazapine
- Pipeline Molecules
- SAGE-547 (Phase III)
- SAGE-217 (Phase II)
- Ganaxolone (Phase II)
- By Geography
- North America
- Europe
- U.K
- Germany
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of Middle East & Africa
The postpartum depression treatment market comprises various industrial players namely Allergan Plc., Anikem Laboratories, Cipla Ltd., Eli Lilly and Company, Intas Pharmaceutical, Ltd., Marinus Pharmaceuticals, Inc., Mylan N.V., Pfizer, Inc., SAGE Therapeutics, Inc., Sun Pharmaceuticals Industries, Ltd. and others.
This report offers:
- An overview of global postpartum depression treatment market
- Market outlook and in depth analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 as the base year
- Annual growth rates for the period from 2018 to 2026 pertaining to the entire market and each segment have also been included in this report
- A complete overview on pipeline molecules
- Qualitative information with respect to market drivers, opportunities and restraints
- A complete understanding on the competitive landscape and profiles of key market players
